Amanda Reiman, PhD, led a discussion on the implications of rescheduling cannabis, with panelists including Dr. Daniele Piomelli, Ethan Fallon, Aaron Smith, Dr. Jordan Tischler, and Steph Sherer. The panelists discussed the potential impact of rescheduling on research, policy, and the cannabis industry, including the reduction of administrative and regulatory burdens for researchers, the potential for more research into therapeutic mechanisms, and the potential for federal agencies like the EPA and FDA to become more involved in cannabis regulation. The panelists also discussed the potential impact of rescheduling on the urgency to pass legislation legalizing or decriminalizing cannabis under state and federal laws and where they would ideally place cannabis in the scheduling system.